MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/cns.70324

Медицинская библиотека · CNS neuroscience & therapeutics · 2025

The Restoration of Energy Pathways Indicates the Efficacy of Ketamine Treatment in Depression: A Metabolomic Analysis.

You Zerui, Lan Xiaofeng, Wang Chengyu, Liu Haiying, Li Weicheng, Mai Siming, Liu Haiyan, Zhang Fan, Liu Guanxi, Chen Xiaoyu, Ye Yanxiang, Zhou Yanling, Ning Yuping

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

AIMS: Despite the clinical benefits of ketamine in treating major depressive disorder (MDD), some patients exhibit drug resistance, and the intricate mechanisms underlying this await comprehensive explication. We used metabolomics to find biomarkers for ketamine efficacy and uncover its mechanisms of action.

METHODS

The study included 40 MDD patients treated with ketamine in the discovery cohort and 24 patients in the validation cohort. Serum samples from the discovery cohort receiving ketamine were analyzed using ultra performance liquid chromatography-mass spectrometry to study metabolomic changes and identify potential biomarkers. Metabolic alterations were evaluated pre- and post-ketamine treatment. Spearman correlation was applied to examine the relationship between metabolite alterations and depressive symptom changes. In addition, potential biomarkers, particularly thyroxine, were investigated through quantitative measurements in the validation cohort.

RESULTS

We found that energy metabolite changes (adenosine triphosphate, adenosine diphosphate [ADP], pyruvate) were different in responders versus non-responders. The magnitude of the ADP shift was strongly correlated with the rate of reduction in Montgomery-Asberg Depression Rating Scale (MADRS) scores (Rho = 0.48, pFDR = 0.018). Additionally, baseline free triiodothyronine (FT3) levels are inversely associated with the rate of MADRS reduction (Rho = -0.645, p = 0.017).

CONCLUSIONS

Ketamine ameliorates depressive symptoms by modulating metabolic pathways linked to energy metabolism. Low baseline FT3 levels appear to predict a positive response in MDD patients, suggesting FT3 has potential as a biological marker for clinical ketamine treatment.

TRIAL REGISTRATION: ChiCTR-OOC-17012239.

Для цитирования: You Zerui, Lan Xiaofeng, Wang Chengyu, Liu Haiying, Li Weicheng, Mai Siming, Liu Haiyan, Zhang Fan, Liu Guanxi, Chen Xiaoyu, Ye Yanxiang, Zhou Yanling, Ning Yuping. The Restoration of Energy Pathways Indicates the Efficacy of Ketamine Treatment in Depression: A Metabolomic Analysis.. CNS neuroscience & therapeutics. 2025. DOI: 10.1111/cns.70324.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.